Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute...
Apr 26, 2013 | sacbee.com
PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc...
Read more...
Xencor antibody MOR208 Fc ADCC B-cell XmAb B-ALL MorphoSys CD19 acute